BIOR vs. CPIX, NRSN, BFRG, GDTC, DMTK, INDP, MEIP, ONCT, SYBX, and ONTX
Should you be buying Biora Therapeutics stock or one of its competitors? The main competitors of Biora Therapeutics include Cumberland Pharmaceuticals (CPIX), NeuroSense Therapeutics (NRSN), Bullfrog AI (BFRG), CytoMed Therapeutics (GDTC), DermTech (DMTK), Indaptus Therapeutics (INDP), MEI Pharma (MEIP), Oncternal Therapeutics (ONCT), Synlogic (SYBX), and Onconova Therapeutics (ONTX). These companies are all part of the "medical" sector.
Biora Therapeutics (NASDAQ:BIOR) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, community ranking, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.
43.7% of Biora Therapeutics shares are held by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 23.2% of Biora Therapeutics shares are held by insiders. Comparatively, 43.3% of Cumberland Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Cumberland Pharmaceuticals had 29 more articles in the media than Biora Therapeutics. MarketBeat recorded 36 mentions for Cumberland Pharmaceuticals and 7 mentions for Biora Therapeutics. Biora Therapeutics' average media sentiment score of 0.68 beat Cumberland Pharmaceuticals' score of -0.11 indicating that Biora Therapeutics is being referred to more favorably in the media.
Cumberland Pharmaceuticals has higher revenue and earnings than Biora Therapeutics. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Biora Therapeutics, indicating that it is currently the more affordable of the two stocks.
Biora Therapeutics has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500.
Biora Therapeutics has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -15.87%. Cumberland Pharmaceuticals' return on equity of 6.84% beat Biora Therapeutics' return on equity.
Cumberland Pharmaceuticals received 183 more outperform votes than Biora Therapeutics when rated by MarketBeat users. However, 66.67% of users gave Biora Therapeutics an outperform vote while only 45.39% of users gave Cumberland Pharmaceuticals an outperform vote.
Summary
Cumberland Pharmaceuticals beats Biora Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Biora Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIOR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biora Therapeutics Competitors List
Related Companies and Tools
